As of Wednesday, December 31, Rain Enhancement Technologies Holdco, Inc.’s RAIN share price has dipped by 13.90%, which has ...
Rain Oncology's stock has fallen near 25% following postponement of milademetan's top-line results and increased net losses reported in Q4 2022 and the full year 2022. Investors may be concerned that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback